Protocol for a 1‐year randomised, controlled, parallel group, open‐label trial on the effects and feasibility of time‐restricted eating in individuals with type 2 diabetes‐ The REStricted Eating Time in the treatment of type 2 diabetes ( RESET2 ) trial
Diabetic Medicine · 2025
DOI: 10.1111/dme.15506 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Diabetic Medicine, 2025. Verfasst von Anne-Ditte Termannsen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Overweight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
Time‐restricted eating (TRE) limits the time for food intake to typically 6–10 h/day without other dietary restrictions. The aim of the RESET2 (the REStricted Eating Time in the treatment of type 2 diabetes) trial is to investigate the effects on glycaemic control (HbA 1c ) and the feasibility of a 1‐year TRE intervention in individuals with overweight/obesity and type 2 diabetes. The aim of the present paper is to describe the protocol for the RESET2 trial.
Methods
RESET2 is a randomised, controlled, parallel‐group, open‐label trial. One hundred and sixty individuals with type 2 diabetes (HbA 1c >53 mmol/mol (>7.0%)), and Body Mass Index ≥25 kg/m 2 will be randomised to standard care plus TRE, or to standard care and habitual living. Both the intervention and control group will follow standard diabetes care including regular clinical visits 3–4 times/year. The intervention is divided into two periods: (1) a 3‐month TRE period with a fixed eating window with a self‐selected timing to obtain data from the participants' experiences with TRE and (2) a 9‐month individually adjusted TRE period. Participants in the TRE group will be instructed to reduce their eating window by a minimum of 3 h/day compared to the habitual eating window and with an eating window of 8–10 h/day. Test days will be scheduled at baseline, after 3 months and after 1 year. The primary outcome is HbA 1c (evaluated 3 months and 1 year after randomisation) and secondary outcomes are body weight, fat mass, continuous glucose monitoring derived time‐in‐range and use of antidiabetic medicine (evaluated 1 year after randomisation). Additionally, we will conduct a process evaluation to assess whether the TRE intervention functioned as hypothesised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Salk Institute for Biological Studies, San Diego, California, USA.
- School of Psychology, University of Leeds, Leeds, UK.
- Novo Nordisk A/S, Søborg, Denmark.
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Anne-Ditte Termannsen, Annemarie Varming, Natasja Bjerre, Helena Z Wodschow, Gitte S Hansen, Nicole J Jensen, Frederik Persson, Jonatan I Bagger, Satchidananda Panda, Graham Finlayson, Bettina Ewers, Dorte L Hansen, Kirsten Nørgaard, Jørgen Rungby, Louise G Grunnet, Martin B Blond, Nana F Hempler, Kristine Færch, Jonas S Quist
Förderung
- Novo Nordisk Fonden
Zitieren
APA
Termannsen, A. D., Varming, A., Bjerre, N., Wodschow, H. Z., Hansen, G. S., Jensen, N. J., Persson, F., Bagger, J. I., Panda, S., Finlayson, G., Ewers, B., Hansen, D. L., Nørgaard, K., Rungby, J., Grunnet, L. G., Blond, M. B., Hempler, N. F., Færch, K., & Quist, J. S. (2025). Protocol for a 1‐year randomised, controlled, parallel group, open‐label trial on the effects and feasibility of time‐restricted eating in individuals with type 2 diabetes‐ The REStricted Eating Time in the treatment of type 2 diabetes ( RESET2 ) trial. Diabetic Medicine. https://doi.org/10.1111/dme.15506
Vancouver
Termannsen AD, Varming A, Bjerre N, Wodschow HZ, Hansen GS, Jensen NJ, et al. Protocol for a 1‐year randomised, controlled, parallel group, open‐label trial on the effects and feasibility of time‐restricted eating in individuals with type 2 diabetes‐ The REStricted Eating Time in the treatment of type 2 diabetes ( RESET2 ) trial. Diabetic Medicine. 2025. doi:10.1111/dme.15506
BibTeX
@article{Termannsen2025,
author = {Termannsen, Anne-Ditte and Varming, Annemarie and Bjerre, Natasja and Wodschow, Helena Z and Hansen, Gitte S and Jensen, Nicole J and Persson, Frederik and Bagger, Jonatan I and Panda, Satchidananda and Finlayson, Graham and Ewers, Bettina and Hansen, Dorte L and Nørgaard, Kirsten and Rungby, Jørgen and Grunnet, Louise G and Blond, Martin B and Hempler, Nana F and Færch, Kristine and Quist, Jonas S},
title = {Protocol for a 1‐year randomised, controlled, parallel group, open‐label trial on the effects and feasibility of time‐restricted eating in individuals with type 2 diabetes‐ The REStricted Eating Time in the treatment of type 2 diabetes ( RESET2 ) trial},
journal = {Diabetic Medicine},
year = {2025},
doi = {10.1111/dme.15506}
}
EUVIMED